Tirzepatide wiki explained: drug class, FDA-approved uses, dosing, side effects, and why compounded or research-grade versions carry real risks.
Tirzepatide is a once-weekly injectable prescription medicine approved by the FDA for type 2 diabetes and for chronic weight management. A tirzepatide wiki entry is a condensed drug reference covering its class, mechanism, approved uses, dosing, side effects, and legal status. This guide summarizes those facts — the same core information you would find on a tirzepatide wikipedia page — and adds context that short reference entries often skip.
Tirzepatide at a Glance
| Attribute | Detail |
|---|---|
| Generic name | Tirzepatide |
| Brand names | Mounjaro (type 2 diabetes), Zepbound (chronic weight management) |
| Drug class | Dual GIP and GLP-1 receptor agonist |
| Route | Subcutaneous injection, once weekly |
| Half-life | About 5 days |
| Manufacturer | Eli Lilly and Company |
| FDA approval | May 2022 for Mounjaro; November 2023 for Zepbound |
Tirzepatide is a dual GIP and GLP-1 receptor agonist, which is what separates it from single-target GLP-1 medicines like semaglutide. It is a prescription drug, so it is not sold over the counter, and raw or "research-grade" powder is not an FDA-approved form of the medication.
How Tirzepatide Works
Tirzepatide mimics two naturally occurring gut hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Together, those signals change how the body handles blood sugar and appetite.
- Insulin release: It increases insulin secretion when blood glucose is elevated, which lowers the risk of hypoglycemia on its own.
- Glucagon suppression: It reduces glucagon secretion, limiting glucose release from the liver.
- Slower digestion: It delays gastric emptying, which extends fullness after meals.
- Appetite signaling: It acts on appetite centers in the brain, reducing overall calorie intake.
Weight loss from tirzepatide comes from a combination of reduced appetite and slower digestion, not from a stimulant effect. The drug does not work instantly; most people need several weeks of dose escalation before the full effect appears.
Approved Uses and Dosing
Type 2 diabetes (Mounjaro)
Mounjaro is approved to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. It is often prescribed when metformin alone is not enough.
Chronic weight management (Zepbound)
Zepbound is approved for adults with obesity or with overweight plus at least one weight-related condition, such as high blood pressure or type 2 diabetes. It is used together with a reduced-calorie diet and increased physical activity.
Dosing follows a standard step-up schedule in both cases: 2.5 mg weekly for four weeks, then 5 mg weekly, with increases of 2.5 mg at intervals as tolerated up to a maximum of 15 mg weekly. The 2.5 mg starting dose is not intended for blood sugar control or weight loss on its own — it exists to reduce side effects.
How Tirzepatide Compares With Other Drugs
| Drug | Mechanism | Approved uses | Average weight change in pivotal trials |
|---|---|---|---|
| Tirzepatide | Dual GIP and GLP-1 agonist | Type 2 diabetes, chronic weight management | About 21% at 15 mg over 72 weeks (SURMOUNT-1) |
| Semaglutide | GLP-1 agonist only | Type 2 diabetes, chronic weight management | About 15% at 2.4 mg over 68 weeks (STEP-1) |
| Liraglutide | GLP-1 agonist only | Type 2 diabetes, chronic weight management | About 8% at 3.0 mg (SCALE) |
Those figures are group averages from specific trials, not predictions for any one person. Head-to-head data (SURMOUNT-5) found tirzepatide produced greater average weight loss than semaglutide at their top approved doses.
Side Effects and Safety Warnings
Most side effects are gastrointestinal and tend to ease after a few weeks at a stable dose. Common complaints include nausea, vomiting, diarrhea, constipation, burping, and injection-site reactions.
More serious risks — though less common — include pancreatitis, gallbladder disease, and hypoglycemia when used with insulin or sulfonylureas. Tirzepatide carries a boxed warning about thyroid C-cell tumors seen in rodents and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Tirzepatide is not recommended during pregnancy, and anyone with a history of pancreatitis, kidney disease, or diabetic retinopathy should discuss risks with a clinician first. Report severe abdominal pain, persistent vomiting, or vision changes promptly.
Compounded Tirzepatide, Research Peptides, and Reliable Sources
Compounded tirzepatide became popular when brand-name supply was tight. Regulators have since moved to wind down large-scale compounding, and compounded versions are not FDA-approved, so strength and purity can vary.
People who buy lyophilized powder often look for a tirzepatide bac water calculator, but dilution math cannot turn an unapproved product into a pharmacy-grade medicine. Forum questions such as how much bac water to reconstitute 20mg tirzepatide typically get answered by strangers rather than clinicians, and injectable dosing errors can cause genuine harm.
Some users also compare aod 9604 vs tirzepatide, weighing a growth-hormone fragment peptide against a dual incretin agonist. There is no published human trial data on aod 9604 and tirzepatide together, so interaction, dosing, and long-term safety questions remain unanswered. Combining any prescription drug with an unapproved peptide should be discussed with a licensed healthcare professional.
For dependable reference material, use the FDA-approved prescribing information, DailyMed, PubMed, and the manufacturer's published trial results. A pharmacist or prescriber can translate those facts into guidance for your situation.
Frequently Asked Questions
Is tirzepatide the same as Mounjaro and Zepbound?
Yes — tirzepatide is the generic name, and Mounjaro and Zepbound are two brand names for the same active drug from Eli Lilly. Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management. Their dosing schedules and side effect profiles are essentially the same.
How is tirzepatide different from semaglutide?
Tirzepatide targets both GIP and GLP-1 receptors, while semaglutide targets only GLP-1. In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide at their highest approved doses. Both are once-weekly injections with similar gastrointestinal side effects.
Can you reconstitute tirzepatide powder at home?
Tirzepatide is FDA-approved only as a ready-to-use pen or single-dose vial, not as a powder for home mixing. Lyophilized "tirzepatide" sold online is an unapproved research chemical with no guaranteed identity, purity, or strength. Reconstituting it yourself carries real risks, including dosing errors and contamination.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.